BTIG analyst David Larsen lowered the firm’s price target on Evolent Health (EVH) to $8 from $10 but keeps a Buy rating on the shares after its Q4 revenue came in light of the firm’s estimates. The company’s new CFO, Mario Ramos is booking substantial reserves for new contracts however and as the year progresses, these reserves may be released if costs are kept under control, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $4 from $9 at Canaccord
- Evolent Health: Conservative Guidance and Elevated Reserves Set the Stage for 2026 Margin Upside and Support a Buy Rating
- Evolent Health downgraded to Sector Weight from Overweight at KeyBanc
- Evolent Health reports Q4 adjusted EPS 8c vs. (2c) last year
- Evolent Health sees FY26 revenue $2.4B-$2.6B, consensus $2.38B